Currently RTRI technology has been commercialized by two manufacturers as 1) Asante HIV-1 Rapid Recency Assay (Sedia Biosciences, Portland, OR, USA) and 2) Maxim Swift Recent Infection Assay (Maxim Biomedical Incorporated, Rockville, MD, USA). Asante is available as 100 tests or 20 tests per kit, while Maxim Swift RIA is available as 20 tests per kit. Both test formats have undergone extensive in-house evaluation and validation at CDC and independently by other laboratories. In all settings, the tests performed well with acceptable performances for recent infection detection, compared to LAg-Avidity EIA.
The International Laboratory Branch (ILB) within CDC is working with additional manufacturers to transfer this technology successfully. When RTRI kits from new manufacturers are validated and approved, additional notification will be shared.